182 related articles for article (PubMed ID: 35974143)
1. PACT promotes the metastasis of basal-like breast cancer through Rac1 SUMOylation and activation.
Wei L; Wang W; Yao J; Cui Z; Xu Z; Ding H; Wu X; Wang D; Luo J; Ke ZJ
Oncogene; 2022 Sep; 41(37):4282-4294. PubMed ID: 35974143
[TBL] [Abstract][Full Text] [Related]
2. The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and activation, leading to G₁ arrest.
Bennett RL; Pan Y; Christian J; Hui T; May WS
Cell Cycle; 2012 Jan; 11(2):407-17. PubMed ID: 22214662
[TBL] [Abstract][Full Text] [Related]
3. Faciogenital Dysplasia 5 supports cancer stem cell traits in basal-like breast cancer by enhancing EGFR stability.
Li K; Zhang TT; Zhao CX; Wang F; Cui B; Yang ZN; Lv XX; Yeerjiang Z; Yuan YF; Yu JM; Wang ZH; Zhang XW; Yu JJ; Liu SS; Shang S; Huang B; Hua F; Hu ZW
Sci Transl Med; 2021 Mar; 13(586):. PubMed ID: 33762435
[TBL] [Abstract][Full Text] [Related]
4. P-cadherin and vimentin are useful basal markers in breast cancers.
Tsang JY; Au SK; Ni YB; Shao MM; Siu WM; Hui SW; Chan SK; Chan KW; Kwok YK; Chan KF; Tse GM
Hum Pathol; 2013 Dec; 44(12):2782-91. PubMed ID: 24139214
[TBL] [Abstract][Full Text] [Related]
5. Basal-like breast cancer with low TGFβ and high TNFα pathway activity is rich in activated memory CD4 T cells and has a good prognosis.
Liu D; Vadgama J; Wu Y
Int J Biol Sci; 2021; 17(3):670-682. PubMed ID: 33767579
[TBL] [Abstract][Full Text] [Related]
6. Nuclear translocation of PLSCR1 activates STAT1 signaling in basal-like breast cancer.
Huang P; Liao R; Chen X; Wu X; Li X; Wang Y; Cao Q; Dong C
Theranostics; 2020; 10(10):4644-4658. PubMed ID: 32292520
[No Abstract] [Full Text] [Related]
7. CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis.
Laine A; Nagelli SG; Farrington C; Butt U; Cvrljevic AN; Vainonen JP; Feringa FM; Grönroos TJ; Gautam P; Khan S; Sihto H; Qiao X; Pavic K; Connolly DC; Kronqvist P; Elo LL; Maurer J; Wennerberg K; Medema RH; Joensuu H; Peuhu E; de Visser K; Narla G; Westermarck J
Cancer Res; 2021 Aug; 81(16):4319-4331. PubMed ID: 34145035
[TBL] [Abstract][Full Text] [Related]
8. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer.
Kashiwagi S; Yashiro M; Takashima T; Aomatsu N; Kawajiri H; Ogawa Y; Onoda N; Ishikawa T; Wakasa K; Hirakawa K
Br J Surg; 2013 Mar; 100(4):490-6. PubMed ID: 23319435
[TBL] [Abstract][Full Text] [Related]
9. RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.
De P; Carlson JH; Jepperson T; Willis S; Leyland-Jones B; Dey N
Oncotarget; 2017 Jan; 8(2):3072-3103. PubMed ID: 27902969
[TBL] [Abstract][Full Text] [Related]
10. p16INK4a expression in basal-like breast carcinoma.
Bohn OL; Fuertes-Camilo M; Navarro L; Saldivar J; Sanchez-Sosa S
Int J Clin Exp Pathol; 2010 Jun; 3(6):600-7. PubMed ID: 20661408
[TBL] [Abstract][Full Text] [Related]
11. Targeting the KLF5-EphA2 axis can restrain cancer stemness and overcome chemoresistance in basal-like breast cancer.
Zhao P; Sun J; Huang X; Zhang X; Liu X; Liu R; Du G; Gan W; Yang C; Tang Y; Chen C; Jiang D
Int J Biol Sci; 2023; 19(6):1861-1874. PubMed ID: 37063424
[TBL] [Abstract][Full Text] [Related]
12. POTEE promotes breast cancer cell malignancy by inducing invadopodia formation through the activation of SUMOylated Rac1.
Martínez-López A; García-Casas A; Infante G; González-Fernández M; Salvador N; Lorente M; Mendiburu-Eliçabe M; Gonzalez-Moreno S; Villarejo-Campos P; Velasco G; Malliri A; Castillo-Lluva S
Mol Oncol; 2024 Mar; 18(3):620-640. PubMed ID: 38098337
[TBL] [Abstract][Full Text] [Related]
13. Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer.
Liu T; Zhang X; Shang M; Zhang Y; Xia B; Niu M; Liu Y; Pang D
J Surg Oncol; 2013 Feb; 107(2):188-94. PubMed ID: 22886823
[TBL] [Abstract][Full Text] [Related]
14. FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer.
Wang QS; Kong PZ; Li XQ; Yang F; Feng YM
Breast Cancer Res; 2015 Feb; 17(1):30. PubMed ID: 25848863
[TBL] [Abstract][Full Text] [Related]
15. Molecular insights on basal-like breast cancer.
Valentin MD; da Silva SD; Privat M; Alaoui-Jamali M; Bignon YJ
Breast Cancer Res Treat; 2012 Jul; 134(1):21-30. PubMed ID: 22234518
[TBL] [Abstract][Full Text] [Related]
16. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
She QB; Gruvberger-Saal SK; Maurer M; Chen Y; Jumppanen M; Su T; Dendy M; Lau YK; Memeo L; Horlings HM; van de Vijver MJ; Isola J; Hibshoosh H; Rosen N; Parsons R; Saal LH
BMC Cancer; 2016 Aug; 16():587. PubMed ID: 27484095
[TBL] [Abstract][Full Text] [Related]
17. Single-gene diagnostic assay for rapid subclassification of basal like breast cancer with mRNA targeted antisense oligonucleotide capped molecular probe.
Moitra P; Alafeef M; Dighe K; Pan D
Biosens Bioelectron; 2022 Jul; 207():114178. PubMed ID: 35316757
[TBL] [Abstract][Full Text] [Related]
18. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.
Cai J; Tian AX; Wang QS; Kong PZ; Du X; Li XQ; Feng YM
Cancer Lett; 2015 Oct; 367(2):129-37. PubMed ID: 26210254
[TBL] [Abstract][Full Text] [Related]
19. Basal phenotype breast cancer: implications for treatment and prognosis.
Pazaiti A; Fentiman IS
Womens Health (Lond); 2011 Mar; 7(2):181-202. PubMed ID: 21410345
[TBL] [Abstract][Full Text] [Related]
20. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Rakha EA; Elsheikh SE; Aleskandarany MA; Habashi HO; Green AR; Powe DG; El-Sayed ME; Benhasouna A; Brunet JS; Akslen LA; Evans AJ; Blamey R; Reis-Filho JS; Foulkes WD; Ellis IO
Clin Cancer Res; 2009 Apr; 15(7):2302-10. PubMed ID: 19318481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
